Lariboisière Hospital is a hospital in the 10th arrondissement of Paris, France. The hospital was one of several built following the second cholera pandemic, which had reached Paris in 1832, and which led to a new emphasis on hygienic practices in hospitals.

There are 1,333 beds in Hopital Lariboisiere.

During the past decade, Hopital Lariboisiere conducted 192 clinical trials. In the 10-year time frame, 192 clinical trials started and 27 clinical trials were completed, i.e. on average, 14.1% percent of trials that started reached the finish line to date. In the past 5 years, 104 clinical trials started and 18 clinical trials were completed. i.e. 17.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital Lariboisiere" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 41 trials, followed by "Hopital Lariboisière" with 12 trials sponsored, "French Cardiology Society" with 10 trials sponsored, "Nantes University Hospital" with 8 trials sponsored and "Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives" with 8 trials sponsored. Other sponsors include 214 different institutions and companies that sponsored additional 142 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital Lariboisiere" #1 collaborator was "Ministry of Health, France" with 6 trials as a collaborator, "INSERM UMR-942, Paris, France" with 5 trials as a collaborator, "Gilead Sciences" with 4 trials as a collaborator, "Institut National de la Santé Et de la Recherche Médicale, France" with 4 trials as a collaborator and "Assistance Publique - Hôpitaux de Paris" with 3 trials as a collaborator. Other collaborators include 150 different institutions and companies that were collaborators in the rest 144 trials.

According to Clinical.Site data, the most researched conditions in "Hopital Lariboisiere" are "Alzheimer Disease" (7 trials), "Acute Coronary Syndrome" (6 trials), "Surgery" (6 trials), "Breast Cancer" (5 trials) and "Diabetes Mellitus" (5 trials). Many other conditions were trialed in "Hopital Lariboisiere" in a lesser frequency.

Most popular intervention types in "Hopital Lariboisiere" are "Drug" (121 trials), "Other" (52 trials), "Procedure" (43 trials), "Device" (34 trials) and "Biological" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (31 trials), "placebo" (5 trials), "Apremilast 20mg" (2 trials), "Apremilast 30mg" (2 trials) and "Gantenerumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Lariboisiere" are 273 trials for "All" genders, 21 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hopital Lariboisiere". 12 are not yet recruiting, 51 are recruiting, 25 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 152 completed trials in Hopital Lariboisiere, 2 suspended trials, and 29 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Lariboisiere, 3 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 78 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 20 trials, and there were also 65 trials that are defined as “Not Applicable".